Pilot study on the feasibility, safety and immunogenicity of a personalized neoantigen-targeted immunotherapy (NeoPepVac) in combination with anti-PD-1 or anti-PD-L1 in advanced solid tumors

S.K. Moerk, M. Donia, J.V. Kringelum, T. Bogenrieder, B. Rønø, A.B. Sorensen, A. Draghi, K F Bol, N.V. Petersen, M. Kadivar, S S Hernandez, S. Reker Hadrup, L.V. Andreasen, D. Christensen, P.L. Andersen, I.M. Svane

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Original languageEnglish
Article number111P
JournalAnnals of Oncology
Volume30
Issue numberSupplement_11
ISSN0923-7534
DOIs
Publication statusPublished - 2019
Event ESMO Immuno-Oncology Congress 2019 - Geneva, Switzerland
Duration: 11 Dec 201914 Dec 2019

Conference

Conference ESMO Immuno-Oncology Congress 2019
CountrySwitzerland
CityGeneva
Period11/12/201914/12/2019

Cite this

Moerk, S. K., Donia, M., Kringelum, J. V., Bogenrieder, T., Rønø, B., Sorensen, A. B., Draghi, A., Bol, K. F., Petersen, N. V., Kadivar, M., Hernandez, S. S., Hadrup, S. R., Andreasen, L. V., Christensen, D., Andersen, P. L., & Svane, I. M. (2019). Pilot study on the feasibility, safety and immunogenicity of a personalized neoantigen-targeted immunotherapy (NeoPepVac) in combination with anti-PD-1 or anti-PD-L1 in advanced solid tumors. Annals of Oncology, 30(Supplement_11), [111P]. https://doi.org/10.1093/annonc/mdz451.019